These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 24505595

  • 21. Sorafenib stimulates human skin type mast cell degranulation and maturation.
    Mizukami Y, Sugawara K, Kira Y, Tsuruta D.
    J Dermatol Sci; 2017 Dec; 88(3):308-319. PubMed ID: 28843624
    [Abstract] [Full Text] [Related]

  • 22. Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.
    Kosmider O, Chapuis N, Kaltenbach S, Coriat R, Boudou Rouquette P, Willems L, Chesnais V, Radford-Weiss I, Bardet V, Mayeux P, Tamburini J, Fontenay M, Bouscary D.
    Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):347-50. PubMed ID: 23246161
    [No Abstract] [Full Text] [Related]

  • 23. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [Abstract] [Full Text] [Related]

  • 24. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
    Kashima T, Ohno Y, Tachibana M.
    Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
    [No Abstract] [Full Text] [Related]

  • 25. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
    Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, Wasman J, Dowlati A, Remick SC.
    Thyroid; 2013 May; 23(5):600-4. PubMed ID: 23113752
    [Abstract] [Full Text] [Related]

  • 26. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.
    Sil A, Das NK.
    Indian J Pharmacol; 2014 May; 46(3):334-6. PubMed ID: 24987183
    [Abstract] [Full Text] [Related]

  • 27. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
    Sotiropoulos GC, Nowak KW, Fouzas I, Vernadakis S, Kykalos S, Klein CG, Paul A.
    Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
    [Abstract] [Full Text] [Related]

  • 28. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Shen CT, Qiu ZL, Luo QY.
    Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
    [Abstract] [Full Text] [Related]

  • 29. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
    Park H, Han SH, Kang H, Park K.
    Int J Cardiol; 2012 Sep 20; 160(1):e10-1. PubMed ID: 22289299
    [No Abstract] [Full Text] [Related]

  • 30. Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature.
    Hamdeh S, Upadhyay S, Khanal N, Lanspa S.
    J Gastrointest Cancer; 2016 Dec 20; 47(4):420-422. PubMed ID: 26223483
    [No Abstract] [Full Text] [Related]

  • 31. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
    Herzog TJ, Scambia G, Kim BG, Lhommé C, Markowska J, Ray-Coquard I, Sehouli J, Colombo N, Shan M, Petrenciuc O, Oza A.
    Gynecol Oncol; 2013 Jul 20; 130(1):25-30. PubMed ID: 23591401
    [Abstract] [Full Text] [Related]

  • 32. Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
    Okada K, Nakano Y, Yamasaki K, Nitani C, Fujisaki H, Hara J.
    Cancer Med; 2016 Aug 20; 5(8):1947-9. PubMed ID: 27264843
    [Abstract] [Full Text] [Related]

  • 33. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
    Perricone G, Mancuso A, Belli LS, Mazzarelli C, Zavaglia C.
    Eur J Gastroenterol Hepatol; 2014 May 20; 26(5):577-8. PubMed ID: 24694739
    [No Abstract] [Full Text] [Related]

  • 34. Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
    Prescrire Int; 2016 Feb 20; 25(168):37. PubMed ID: 27042725
    [Abstract] [Full Text] [Related]

  • 35. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
    Grenader T, Rosenbaum E, Zilber S, Bogot N, Shavit L.
    Clin Genitourin Cancer; 2013 Jun 20; 11(2):201-3. PubMed ID: 23266054
    [No Abstract] [Full Text] [Related]

  • 36. Sorafenib in the treatment of thyroid cancer.
    Ferrari SM, Politti U, Spisni R, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A, Fallahi P.
    Expert Rev Anticancer Ther; 2015 Jun 20; 15(8):863-74. PubMed ID: 26152651
    [Abstract] [Full Text] [Related]

  • 37. Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
    Wolber C, Udvardi A, Tatzreiter G, Schneeberger A, Volc-Platzer B.
    J Dtsch Dermatol Ges; 2009 May 20; 7(5):449-52. PubMed ID: 19178612
    [Abstract] [Full Text] [Related]

  • 38. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ.
    Lancet Oncol; 2013 Dec 20; 14(13):1287-94. PubMed ID: 24206640
    [Abstract] [Full Text] [Related]

  • 39. Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib.
    Sato-Sano M, Cury-Martins J, Macarenco R, Domingues RB, Vasconcelos R, Sanches JA.
    J Dtsch Dermatol Ges; 2018 Dec 20; 16(12):1486-1489. PubMed ID: 30466160
    [No Abstract] [Full Text] [Related]

  • 40. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
    Chevreau C, Le Cesne A, Ray-Coquard I, Italiano A, Cioffi A, Isambert N, Robin YM, Fournier C, Clisant S, Chaigneau L, Bay JO, Bompas E, Gauthier E, Blay JY, Penel N.
    Cancer; 2013 Jul 15; 119(14):2639-44. PubMed ID: 23589078
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.